PLYMOUTH MEETING, PA, USA I March 13, 2025 I INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help ...

In a preclinical study, researchers at Children's Hospital of Philadelphia (CHOP) demonstrated a novel gene therapy with ...

Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data ...

This review discusses the current state of multicancer early detection tests, the role of machine learning in their ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

The spy agency's assessment was based on an unspecified intelligence operation code-named "Saaremaa" as well as on ...

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Eve Holding, Inc. ("Eve") reports its fourth quarter and fiscal year 2024 earnings results. Year in review Eve Air Mobility accomplished several milestones on our journey to shape the global Urban Air ...

Learn more about eLife assessments Sleep disturbances are associated with poor long-term memory (LTM) formation, yet the underlying cell types and neural circuits involved have not been fully decoded.

Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a Phase 1 clinical trial of FZ002 for C. difficile treatment. Oral FZ002 is a ...